Overview
- Reports indicate the White House is preparing an executive order that would instruct the Justice Department and the DEA to conclude the ongoing rescheduling review.
- Trump said Monday the administration is "considering" reclassification, citing the goal of enabling broader medical research.
- A move to Schedule III would lower federal restrictions and could ease barriers to FDA‑authorized studies and industry compliance obligations.
- Cannabis equities have surged on the prospect, with Tilray, Canopy Growth, Curaleaf, Cresco Labs, and Trulieve posting strong multi‑day gains.
- Recent outreach included Oval Office talks with cannabis executives and meetings with Health Secretary Robert F. Kennedy Jr. and the FDA commissioner, according to reporting.